NCT04644627View on ClinicalTrials.gov

Topical Gentamicin Nonsense Suppression Therapy of EB

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 11, 2022

Study Completion Date

May 1, 2022

Conditions
Epidermolysis Bullosa
Interventions
DRUG

Gentamicin Sulfate

Topical gentamicin ointment on wounds once daily for 6 weeks

Trial Locations (1)

0424

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT04644627 - Topical Gentamicin Nonsense Suppression Therapy of EB | Biotech Hunter | Biotech Hunter